Research site

Multiprofile Hospital For Active Treatment Dr. Hristo Stambolski EOOD

Bulgaria Ulitsa Starozagorska 16, 6102 Kazanlak, Bulgaria

4 trials recruiting
Schizophrenia · Major depression · Bipolar I disorder
Adult patients

About Specializations

Multiprofile Hospital For Active Treatment Dr. Hristo Stambolski EOOD in Kazanlak, Bulgaria specialises in clinical trials of conditions such as Schizophrenia, Major depression, Bipolar I disorder, Bipolar disorder, and other specialisations. This site conducts important research.

Main research areas of the site

Psychiatry and Psychology – Mental Disorders

The Department of Psychiatry at Multiprofile Hospital for Active Treatment Dr. Hristo Stambolski EOOD is dedicated to improving care for patients with schizophrenia, bipolar disorder, and major depressive disorder. Current research evaluates new therapies that target core symptoms, enhance daily functioning, and monitor long‑term safety.

Reducing negative and cognitive symptoms in schizophrenia
Managing manic episodes associated with bipolar I disorder
Alleviating depressive episodes in bipolar I or II disorder
Treating major depressive disorder with novel agents
Assessing long‑term safety of adjunctive treatments for schizophrenia

Ten active trials, overseen by five investigators, are underway at the Kazanlak site, contributing valuable data to the European mental‑health research landscape.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Ulitsa Starozagorska 166102 KazanlakBulgaria

Open in maps ↗

Recruiting now: 4 trials
Conditions studied: 4

More sites in Kazanlak Bulgaria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

11 clinical trials

Schizophrenia

Recruiting

Investigational

Study on Vafidemstat for Treating Negative Symptoms and Cognitive Impairment in Adults with Schizophrenia

Investigational

Bulgaria

Participants:18–64 years
Substances:Vafidemstat
Sponsor:Oryzon Genomics S.A.

Contact Research Centre

Schizophrenia

Recruiting

Investigational

A study to assess the safety and effectiveness of GXV813 in hospitalized adults with schizophrenia

Investigational

Bulgaria

Participants:18–64 years
Substances:GXV813
Sponsor:Novartis Pharma AG

Contact Research Centre

Schizophrenia

Recruiting

Investigational

A study to evaluate the effectiveness and safety of NBI-1117570 in adults with schizophrenia who require hospital treatment.

Investigational

Bulgaria

Participants:18–64 years
Substances:HTL0022537
Sponsor:Neurocrine Biosciences Inc.

Contact Research Centre

Major depression

Recruiting

Investigational

A study to evaluate the effectiveness and safety of DT-101 in adults with major depressive disorder

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Sponsor:Draig Therapeutics Limited

Contact Research Centre

Major depression

Not yet recruiting

Registered drugNo placebo

Evaluation of Trazodone Hydrochloride for Improving Emotional Blunting in Patients with Major Depressive Disorder

Registered drugNo placebo

Bulgaria

Participants:18–64 years
Substances:TRAZODONE HYDROCHLORIDE
Sponsor:Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesc O A.C.R.A.F. S.p.A.

Contact Research Centre

Bipolar I disorder

Not yet recruiting

InvestigationalNo placebo

A study to evaluate the safety and effectiveness of azetukalner in patients with bipolar depression

InvestigationalNo placebo

Bulgaria

Participants:18–64 years · 65+ years
Substances:Azetukalner
Sponsor:Xenon Pharmaceuticals Inc.

Contact Research Centre

Bipolar I disorder

Not yet recruiting

Investigational

A study to evaluate the effectiveness and safety of azetukalner in patients experiencing depressive episodes associated with bipolar disorder.

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:Azetukalner
Sponsor:Xenon Pharmaceuticals Inc.

Contact Research Centre

Schizophrenia

Not recruiting

InvestigationalNo placebo

Long-term safety study of trospium chloride and xanomeline tartrate combination (KarXT) in patients with inadequately controlled schizophrenia symptoms

InvestigationalNo placebo

Bulgaria

Participants:18–64 years · 65+ years
Substances:Trospium Chloride
Sponsor:Karuna Therapeutics Inc.

Contact Research Centre

Major depression

Not recruiting

Investigational

Study on the Effects of BH-200 (Nelivaptan) for Patients with Major Depressive Disorder

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:Nelivaptan
Sponsor:HMNC Holding GmbH

Contact Research Centre

Bipolar disorder

Not recruiting

Investigational

Study on Lumateperone for Treating Manic Episodes in Bipolar I Disorder Patients

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:Lumateperone
Sponsor:Intra-Cellular Therapies Inc.

Contact Research Centre

Schizophrenia

Not recruiting

Investigational

Study of KarXT (trospium chloride and xanomeline tartrate) in patients with inadequately controlled schizophrenia symptoms

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:Trospium Chloride
Sponsor:Karuna Therapeutics Inc.

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites